Chemokine Therapeutics Announces New President And Chief Executive Officer
Chemokine Therapeutics Corp. announced the appointment of Walter Korz as its new President and Chief Executive Officer (CEO). Mr. Korz succeeds Bashir Jaffer who held the position as Chief Executive Officer on an interim basis since December 2007. Mr. Jaffer will continue to serve the Company as Chief Financial Officer.
Mr. Korz has been with the Company since March 2003 serving as Vice President of Drug Development. His multi-disciplinary experience spans seventeen years in the biotechnology sector as well as an additional ten years in the healthcare sector. He brings with him a broad drug development background, including experience in regulatory, clinical, business development and medical affairs. His experience with therapeutic and diagnostic research drugs encompasses various indications including cancer, multiple sclerosis, rheumatoid arthritis, and psoriasis. Prior to joining Chemokine, from 2000 to 2003 he held the position of Clinical Development Manager with Angiotech Pharmaceuticals overseeing their systemic therapeutics. Mr. Korz's experience includes overseeing the development of diagnostic and therapeutic products with AltaRex Corp. in Edmonton and Boston. His initial drug development, clinical and regulatory experiences were gained with Biomira Inc.
Other news from the department people
